TY - JOUR
T1 - Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity
T2 - Analysis of women in the control arm of the randomized, controlled PATRICIA trial
AU - Castellsagué, Xavier
AU - Paavonen, Jorma
AU - Jaisamrarn, Unnop
AU - Wheeler, Cosette M.
AU - Skinner, S. Rachel
AU - Lehtinen, Matti
AU - Naud, Paulo
AU - Chow, Song Nan
AU - Del Rosario-Raymundo, Maria Rowena
AU - Teixeira, Julio C.
AU - Palmroth, Johanna
AU - De Carvalho, Newton S.
AU - Germar, Maria Julieta V
AU - Peters, Klaus
AU - Garland, Suzanne M.
AU - Szarewski, Anne
AU - Poppe, Willy A J
AU - Romanowski, Barbara
AU - Schwarz, Tino F.
AU - Tjalma, Wiebren A A
AU - Bosch, F. Xavier
AU - Bozonnat, Marie Cecile
AU - Struyf, Frank
AU - Dubin, Gary
AU - Rosillon, Dominique
AU - Baril, Laurence
AU - Denham, I.
AU - Garland, S. M.
AU - Mindel, A.
AU - Skinner, S. R.
AU - De Sutter, P.
AU - Poppe, W. A J
AU - Tjalma, W.
AU - De Carvalho, N. S.
AU - Naud, P.
AU - Teixeira, J. C.
AU - Aoki, F. Y.
AU - Diaz-Mitoma, F.
AU - Dionne, M.
AU - Ferguson, L.
AU - Miller, M.
AU - Papp, K.
AU - Ramjattan, B.
AU - Romanowski, B.
AU - Orr, P. H.
AU - Somani, R.
AU - Apter, D.
AU - Karppa, T.
AU - Kudjoi, N.
AU - Downs, L.
AU - HPV PATRICIA Study Group
N1 - Publisher Copyright:
© 2014 Castellsagué et al.
PY - 2014
Y1 - 2014
N2 - Background: More information is needed about time between sexual initiation and human papillomavirus (HPV) infection and development of cervical precancer. Methods: The objectives were to investigate the time between first sexual activity and detection of first cervical HPV infection or development of first cervical intraepithelial neoplasia (CIN), and associated factors in women from the double-blind, multinational, 4-year PATRICIA trial. PATRICIA enroled women aged 15-25 years with no more than 6 lifetime sexual partners. Women were randomized 1:1 to the HPV-16/18 AS04-adjuvanted vaccine or to control, but only women from the control arm who began sexual intercourse during the study or within 6 months before enrolment, and had no HPV infection detected before the recorded date of their first sexual intercourse, were included in the present analysis. The time between onset of sexual activity and detection of the first cervical HPV infection or development of the first CIN lesion was analyzed using Kaplan-Meier and univariate and multivariable Cox proportional-hazards models. Results: A total of 9337 women were enroled in the control arm of PATRICIA of whom 982 fulfilled the required inclusion criteria for analysis. A cumulative total of 28%, 44%, and 62% of the subjects had HPV infection within 12, 24, and 48 months, respectively. The overall incidence rate was 27.08 per 100 person-years. The most common oncogenic types associated with 6-month persistent infection were HPV-16 (incidence rate: 2.74 per 100 person-years), HPV-51 (2.70), HPV-52 (1.66), HPV-66 (1.14), and HPV-18 (1.09). Increased infection risk was associated with more lifetime sexual partners, being single, Chlamydia trachomatis history, and duration of hormone use. CIN1+ and CIN2+ lesions were most commonly associated with HPV-16, with an overall incidence rate of 1.87 and 1.07 per 100 person-years, respectively. Previous cervical HPV infection was most strongly associated with CIN development. Conclusions: More than 25% of women were infected with HPV within 1 year of beginning sexual activity. Without underestimating the value of vaccination at older ages, our findings emphasize its importance before sexual initiation.
AB - Background: More information is needed about time between sexual initiation and human papillomavirus (HPV) infection and development of cervical precancer. Methods: The objectives were to investigate the time between first sexual activity and detection of first cervical HPV infection or development of first cervical intraepithelial neoplasia (CIN), and associated factors in women from the double-blind, multinational, 4-year PATRICIA trial. PATRICIA enroled women aged 15-25 years with no more than 6 lifetime sexual partners. Women were randomized 1:1 to the HPV-16/18 AS04-adjuvanted vaccine or to control, but only women from the control arm who began sexual intercourse during the study or within 6 months before enrolment, and had no HPV infection detected before the recorded date of their first sexual intercourse, were included in the present analysis. The time between onset of sexual activity and detection of the first cervical HPV infection or development of the first CIN lesion was analyzed using Kaplan-Meier and univariate and multivariable Cox proportional-hazards models. Results: A total of 9337 women were enroled in the control arm of PATRICIA of whom 982 fulfilled the required inclusion criteria for analysis. A cumulative total of 28%, 44%, and 62% of the subjects had HPV infection within 12, 24, and 48 months, respectively. The overall incidence rate was 27.08 per 100 person-years. The most common oncogenic types associated with 6-month persistent infection were HPV-16 (incidence rate: 2.74 per 100 person-years), HPV-51 (2.70), HPV-52 (1.66), HPV-66 (1.14), and HPV-18 (1.09). Increased infection risk was associated with more lifetime sexual partners, being single, Chlamydia trachomatis history, and duration of hormone use. CIN1+ and CIN2+ lesions were most commonly associated with HPV-16, with an overall incidence rate of 1.87 and 1.07 per 100 person-years, respectively. Previous cervical HPV infection was most strongly associated with CIN development. Conclusions: More than 25% of women were infected with HPV within 1 year of beginning sexual activity. Without underestimating the value of vaccination at older ages, our findings emphasize its importance before sexual initiation.
KW - CIN
KW - HPV
KW - Risk
KW - Sexual intercourse
KW - Time
UR - http://www.scopus.com/inward/record.url?scp=84964316120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964316120&partnerID=8YFLogxK
U2 - 10.1186/s12879-014-0551-y
DO - 10.1186/s12879-014-0551-y
M3 - Article
C2 - 25927224
AN - SCOPUS:84964316120
SN - 1471-2334
VL - 14
JO - BMC infectious diseases
JF - BMC infectious diseases
IS - 1
M1 - 551
ER -